A5005971441- CAR-T cell therapy research
- Phagocytosis and Immune Regulation
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Cardiovascular Disease and Adiposity
- Integrated Circuits and Semiconductor Failure Analysis
- CRISPR and Genetic Engineering
- Advancements in Semiconductor Devices and Circuit Design
- Cardiac Valve Diseases and Treatments
- Circular RNAs in diseases
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Virus-based gene therapy research
Southern University of Science and Technology
2024-2025
Shenzhen Third People’s Hospital
2024-2025
Hebei Medical University
2016-2022
Second Hospital of Hebei Medical University
2016-2022
As of September 30, 2023, the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database has received 12 reports secondary T-cell malignancies since first BCMA-/CD19-targeted autologous CAR-T therapies was approved in 2017 (https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html). Consequently, FDA released a statement on November 28, announcing their ongoing investigation into identified risk malignancy, which been associated with severe outcomes such as...
Background/Objectives: The AXL receptor tyrosine kinase is a promising therapeutic target in solid tumors, yet conventional viral vector-engineered CAR-T cells face critical limitations, including risks of insertional mutagenesis and immunogenicity from murine-derived single-chain variable fragments (scFvs). This study aimed to develop evaluate mRNA-engineered fully human (mfhAXL CAR-T) as safer, scalable alternative for tumor immunotherapy. Methods:mfhAXL were generated via...
Abstract Cancer immunotherapy has emerged as the fourth most prevalent approach to tumor treatment, alongside surgery, radiotherapy, and chemotherapy. After several decades of development, chimeric antigen receptor T (CAR‐T) cell therapy, a promising branch adoptive T‐cell demonstrated superior efficacy safety in comparison other therapies treatment cancer. At present, CAR‐T cells are predominantly used treat hematological malignancies, although their application solid tumors is being...
<title>Abstract</title> Background Currently approved CAR-T cells primarily utilize retroviral or lentiviral vectors (LV), posing significant challenges due to their time-consuming and costly nature, associated safety concerns, including insertional mutagenesis. Consequently, mRNA delivery holds promising prospects in cell engineering. AXL represents an ideal target for LV-engineered the treatment of various malignancies, breast, lung, pancreatic cancer. However, anti-tumor activity...
Abstract Purpose To retrospectively investigate the epicardial fat volume with multidetector computed tomography (MDCT) and other risk factors for prevalence of three-vessel coronary lesion. Materials methods MDCT was performed on 424 subjects or without Blood tested triglyceride, high-density lipoprotein (HDL), low-density (LDL), apolipoprotein A (ApoA), B (ApoB), alanine aminotransferase (ALT), aspartate (AST), a, fasting blood glucose. Results Among all subjects, a significant ( P <...